ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
March 05, 2025Antengene announced XPOVIO® (selinexor) was approved for commercialization in Indonesia. It's the first XPO1 inhibitor there. Since 2024, it has been approved in multiple APAC markets for various cancer indications. -
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections
July 26, 2021In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor ...
Pharma Sources Insight January 2025
